Diasorin

Name: Diasorin
Address: Strada Crescentino snc, Saluggia, 13040, IT
Telephone: +390161487093
Price range: Not Applicable

Casa
Italia
Saluggia
Diasorin

Global leader in the laboratory diagnostics market. Starting from 2021, the company also commercializes Life Science products.

DiaSorin is an Italian multinational biotechnology company that produces and markets in vitro diagnostics reagent kits used in immunodiagnostics and molecular diagnostics. The Group was founded in 1968 and is headquartered in Saluggia (Italy). Its line of products used by diagnostic laboratories that are part of hospital facilities or operate independently can meet the needs of the following clini

cal areas: infectious diseases, cardiac markers, bone metabolism, hepatitis and retrovirus, oncology and endocrinology. DiaSorin can offer the market an assay menu that is unique for its width and presence of specialty tests, which identify us as “the” in vitro diagnostics specialist. DiaSorin also provides Life Science products that have a wide range of applications including academic and scientific research, public health and food safety, plant pathogens detection and cell counts, viability, and cell health analyses.

08/06/2026

Carbapenemase-producing organisms (CPOs) continue to rise, with CDC data showing a 3.8% national increase in 2025. This trend is more than a statistic; it’s an early warning that resistant mechanisms are continuing to spread.

The need for rapid, molecular detection has never been more urgent.

Check out our blog to learn more about these gram-negative threats and how the LIAISON PLEX® Gram-Negative Blood Culture Assay supports broader coverage and faster turnaround for more effective detection and containment.

Read more: https://hubs.li/Q04kq8Xf0

03/06/2026

What does it take to make diagnostic stewardship truly actionable in today’s clinical environment?

Join us at ASM Microbe 2026 for a live Beyond the Result podcast recording that will include Dr. David Gaston, Medical Director, Molecular Infectious Disease Laboratory at Vanderbilt University Medical Center.

In this session, we’ll explore how innovations in flexible syndromic testing are helping healthcare organizations:
• Deliver more tailored diagnostic strategies
• Enable faster, more informed clinical decisions
• Strengthen diagnostic stewardship across the care continuum

Hear from Dr. Gaston and two other industry leaders in laboratory medicine in support of improving patient outcomes through smarter, more efficient diagnostic testing practices.

Learn more: https://hubs.li/Q04hZ7VR0

01/06/2026

We are pleased to be featured in an upcoming ASM Microbe Journal Club session highlighting a recent publication on the 𝐋𝐈𝐀𝐈𝐒𝐎𝐍 𝐏𝐋𝐄𝐗® 𝐑𝐞𝐬𝐩𝐢𝐫𝐚𝐭𝐨𝐫𝐲 𝐅𝐥𝐞𝐱 𝐀𝐬𝐬𝐚𝐲.

The session will explore age-stratified respiratory pathogen epidemiology and examine the role of customizable syndromic testing in respiratory panel design, drawing from the following publication:

𝐆𝐨𝐧𝐳𝐚𝐥𝐞𝐳 𝐊, 𝐀𝐦𝐢𝐜𝐚𝐫𝐞𝐥𝐥𝐢 𝐆.
Age-Stratified Epidemiology of Respiratory Pathogens and the Value of Customizable Syndromic Testing Using the LIAISON PLEX Respiratory Flex Assay.
https://hubs.li/Q04jBv0g0

Attendees will hear perspectives from academic microbiology leaders representing institutions including Penn Medicine, UC Irvine, the University of Texas Medical Branch, and Johns Hopkins.

Learn more about the Clinical Microbiology Virtual Journal Club on https://hubs.li/Q04jzSGS0: https://hubs.li/Q04jzS9Y0

We look forward to connecting with you at ASM Microbe, Booth #1301.

31/05/2026

The rise of carbapenemase-producing organisms (CPOs) remains a serious challenge for healthcare systems. CDC data from 2025 shows a 3.8% national increase, underscoring the urgent need for faster, molecular detection.

Visit our blog to learn more about this growing threat and how molecular panels such as the LIAISON PLEX® Gram-Negative Blood Culture Assay deliver broader coverage and faster turnaround to support containment and stewardship.

Learn more: https://hubs.ly/Q04jvZQv0

30/05/2026

Join us at ASM Microbe 2026 for a live Beyond the Result podcast recording featuring Dr. Linoj Samuel, Division Head, Clinical Microbiology, Henry Ford Health System.

This session will explore the practical realities of implementing diagnostic stewardship through flexible syndromic testing, including:
• Integrating diagnostics into everyday clinical workflows
• Bridging the gap between lab data and clinical decision-making
• Supporting antimicrobial stewardship through smarter test utilization

Tune in to hear from Dr. Samuel and esteemed laboratorians for insights into how laboratories and clinicians work together to drive better patient outcomes.

Learn more: https://hubs.li/Q04hXF8j0

26/05/2026

Attending ASM Microbe 2026? Tune in for a live Beyond the Result podcast recording that will include Dr. Allison Chambliss, Director of Laboratory Stewardship, UCLA, where she and two other esteemed panelists will explore how healthcare systems can move from theory to action.

This session will discuss how flexible syndromic testing can help organizations:
• Move beyond one-size-fits-all diagnostics
• Better match testing to patient presentation
• Improve utilization and stewardship efforts

Step into the future of diagnostic testing at ASM 2026 with Dr. Chambliss and other industry leaders as they share actionable insights you can't afford to miss.

Learn more: https://hubs.li/Q04hYvXv0

25/05/2026

How do you reduce respiratory overtesting and cost without losing the confidence of broad panels?

In this short video, Nicholas Decker of Holland Hospital shares how his team utilizes the LIAISON PLEX® Respiratory Flex Assay to strengthen stewardship and align testing choices with payor guidelines.

See what Holland Hospital achieved, and what your lab could, too.

Watch the video to learn more: https://hubs.li/Q04fZ0pQ0

23/05/2026

Diasorin is proud to share a new Infection Control Today article by Ayaz Majid, PhD, highlighting how rapid molecular diagnostics help healthcare facilities stop the spread of multi-drug-resistant C. auris.

As cases rise globally, targeted screening via fast, reliable testing empower teams to act quickly, protect patients, and prevent outbreaks.

Read the article: Breaking the chain of transmission to prevent C. auris infections in healthcare settings https://hubs.li/Q04h074y0

Diasorin is committed to supporting clinicians with innovative diagnostic solutions. Learn more about the De Novo granted Simplexa® C. auris Direct assay here: https://hubs.li/Q04g_pxk0

22/05/2026

Broad panels and low-value testing may feel safer, but they can add risk and cost without improving patient outcomes.

In our second laboratorian-authored blog in our series, Dr. Meghan Starolis, MS, PhD, HCLD (ABB), Senior Science Director of Infectious Disease at Quest Diagnostics, explains why diagnostic stewardship matters now more than ever, and how the lab can lead.

If you’re looking to design meaningful diagnostic testing strategies, this is a must read!

Read the full blog here: https://hubs.li/Q04hCzxQ0

11/05/2026

In case you missed it we’ve submitted the LIAISON PLEX® Gastrointestinal (GI) Flex Assay to the FDA for 510(k) clearance.

With the LIAISON PLEX® System, labs can test what’s clinically appropriate, report what matters, and pay only for what’s used—helping reduce cost burdens for both patients and laboratories.

Sign up for our email list to receive the latest updates on LIAISON PLEX System, including access to a recent presentation at SCASM: https://hubs.li/Q04g7dRj0

Note: The LIAISON PLEX® GI Flex Assay is currently under FDA review and is not yet available for sale or clinical use in the United States.

Indirizzo

Strada Crescentino Snc
Saluggia
13040

Telefono

+390161487093

Sito Web

http://www.diasorin.com/

Notifiche

Lasciando la tua email puoi essere il primo a sapere quando Diasorin pubblica notizie e promozioni. Il tuo indirizzo email non verrà utilizzato per nessun altro scopo e potrai annullare l'iscrizione in qualsiasi momento.